Single-use disposable technologies for biopharmaceutical manufacturing

Trends in Biotechnology

Volumn 31, Issue 3, 2013, Pages 147-154

  Shukla, Abhinav A ^a   Gottschalk, Uwe ^b  

^a KBI Biopharma   (United States)

^b SARTORIUS STEDIM BIOTECH GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CURRENT GOOD MANUFACTURING PRACTICES; DISPOSABLE TECHNOLOGY; DOWNSTREAM PURIFICATIONS; IMPROVE PERFORMANCE; MANUFACTURING FACILITY; MANUFACTURING PROCESS; PRODUCTION FACILITY; TECHNICAL ADVANCES;

TECHNOLOGY;

MANUFACTURE;

BIOREACTOR; CELL CULTURE; CENTRIFUGATION; CENTRIFUGE; CHROMATOGRAPHY; DOWNSTREAM PROCESSING; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG QUALITY; FILTER; FILTRATION; GOOD MANUFACTURING PRACTICE; HUMAN; MICROFILTRATION; PHARMACEUTICS; PRIORITY JOURNAL; REVIEW; SINGLE USE DISPOSABLE TECHNOLOGY; TISSUE CULTURE; WASTE DISPOSAL;

BIOLOGICAL AGENTS; BIOTECHNOLOGY; DISPOSABLE EQUIPMENT; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84875253542     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2012.10.004     Document Type: Review

References (43)

1. Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients 2000, International Conference for Harmonization, ICH.
2. FDA Equipment Cleaning and Maintenance 2004, FDA.
3. FDA Guide to Inspections Validation of Cleaning Processes 2006, FDA.
4. Gottschalk U. Disposables in downstream processing. Advances in Biochemical Engineering/Biotechnology 2010, Vol. 115:171-183. Springer. R. Eibl, D. Eibl (Eds.).
5. Pais-Chanfrau J., et al. The impact of disposables on project economics in a new antibody plant: a case study. BioPharm. Int. 2009, 22:62-74.
6. Langer, E.S. (2012) 9th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. A Study of Biotherapeutic Developers and Contract Manufacturing Organizations, BioPlan Associates.
7. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 2010, 28:917-924.
8. Olsen N., Stein M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 2004, 350:2167-2179.
9. Rathore A. Follow-on protein products: scientific issues, development and challenges. Trends Biotechnol. 2009, 27:698-705.
10. Gottschalk U., et al. The need for innovation in biomanufacturing. Nat. Biotechnol. 2012, 30:489-492.
11. Kelley B. Industrialization of mAb production technology. Monocl. Antibod. 2009, 1:443-452.
12. Singh V. Disposable bioreactor for cell culture using wave induced agitation. Cytotechnology 1999, 30:149-158.
13. Haldankar R., et al. Serum-free suspension large-scale transient transfection of CHO cells in WAVE bioreactors. Mol. Biotechnol. 2006, 34:191-199.
14. De Jesusa M.J., et al. TubeSpin satellites: a fast track approach for process development with animal cells using shaking technology. Biochem. Eng. J. 2004, 17:217-223.
15. Baldi L., et al. Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol. Prog. 2005, 21:148-153.
16. Stettler M., et al. New disposable tubes for rapid and precise biomass assessment for suspension cultures of mammalian cells. Biotechnol. Bioeng. 2006, 95:1228-1233.
17. Muller N., et al. Scalable transient gene expression in Chinese hamster ovary cells in instrumented and noninstrumented cultivation systems. Biotechnol. Lett. 2007, 29:703-711.
18. Shukla A., Kandula J. Harvest and recovery of monoclonal antibodies from large-scale mammalian cell culture. BioPharm. Int. 2008, 21:34-45.
19. Van Reis R., Zydney A. Membrane separations in biotechnology. Curr. Opin. Biotechnol. 2001, 12:208-211.
20. Shukla A., et al. Vertical Integration of disposables in biopharmaceutical drug substance manufacturing. Bioprocess Int. 2012, 10:34-47.
21. Fuller M., Pora H. Introducing disposable systems into biomanufacturing - a CMO case study. Bioprocess Int. 2008, 6:30-36.
22. Wilson J. A fully disposable monoclonal antibody manufacturing train. Bioprocess Int. 2006, 4:34-36.
23. Shukla A., Thommes J. Advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28:253-261.
24. Walter J.K. Strategies and considerations for advanced economy in downstream processing of biopharmaceutical proteins. Bioseparation and Bioprocessing. Processing, Quality and Characterization, Economics, Safety and Hygiene 1998, 447-460. Wiley VCH. G. Subramanian (Ed.).
25. Gottschalk U. New and unknown challenges facing biomanufacturing. BioPharm. Int. 2005, 18:24-28.
26. Gottschalk U. The Renaissance of protein purification. BioPharm. Int. 2006, 19:8-9.
27. Altaras G., et al. Quantitation of interaction of lipids with polymer surfaces in cell culture. Biotechnol. Bioeng. 2007, 96:999-1007.
28. Okonkowski J., et al. Cholesterol delivery to NS0 cells: challenges and solutions in disposable linear low-density polyethylene-based bioreactors. J. Biosci. Bioeng. 2007, 103:50-59.
29. Tao Y., et al. Novel cholesterol feeding strategy enables cultivation of NS0 cells in low-density polyethylene-based bioreactors. Biotechnol. Lett. 2012, 34:1453-1458.
30. Smith-McCollum B., Rosin L. The Bioprocess Systems Alliance. Bioprocess Int. 2006, 4:6-8.
31. FDA Guidance for Industry: PAT - a Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance 2004, FDA.
32. Hinz D.C. Process analytical technologies in the pharmaceutical industry: the FDA's PAT initiative. Anal. Bioanal. Chem. 2006, 384:1036-1042.
33. Yu L.X. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res. 2008, 25:781-791.
34. FDA (2003) Final Report on Pharmaceutical cGMPs for the 21st Century - a Risk-based Approach, FDA.
35. De Beer T., et al. Near infrared and Raman spectroscopy for the in-process monitoring of pharmaceutical production processes. Int. J. Pharm. 2011, 417:32-47.
36. Hou Y., et al. Improved Process Analytical Technology (PAT) for Protein A chromatography using predictive PCA tools. Biotechnol. Bioeng. 2011, 108:59-68.
37. Kuribayashi R., et al. Rapid evaluation for heterogeneities in monoclonal antibodies by liquid chromatography/mass spectrometry with a column-switching system. J. Pharm. Biomed. Anal. 2012, 67-68:1-9.
38. Eibl D., et al. Single-use equipment in biopharmaceutical manufacture: a brief introduction. Single-use Technology in Biopharmaceutical Manufacture 2011, 1-11. John Wiley & Sons. R. Eibl, D. Eibl (Eds.).
39. Oosterhuis N., van den Berg H. How multi-purpose is a single-use bioreactor?. Biopharm. Int. 2011, 24:51-56.
40. Muller N., et al. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol. Bioeng. 2004, 89:400-406.
41. Tissot S., et al. Efficient and reproducible mammalian cell bioprocesses without probes and controllers?. N. Biotechnol. 2011, 28:382-390.
42. Lee B., et al. Characterization of novel pneumatic mixing for single-use bioreactor application. BMC Proc. 2011, 5:1-2.
43. Smelko J., et al. Performance of high intensity mammalian fed batch cell cultures in disposable bioreactors. Biotechnol. Prog. 2011, 27:1358-1364.